Dicerna Pharmaceuticals
Market Cap
US$1.5b
Last Updated
2020/02/17 01:09 UTC
Data Sources
Company Financials +
Executive Summary
Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of ribonucleic acid interference (RNAi)-based pharmaceuticals.
Rewards
Risk Analysis
Earnings are forecast to decline by an average of -0.5% per year for the next 3 years
Currently unprofitable and not forecast to become profitable over the next 3 years
Snowflake Analysis
Flawless balance sheet and slightly overvalued.
Share Price & News
How has Dicerna Pharmaceuticals's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: DRNA's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
-2.0%
DRNA
-0.5%
US Biotechs
1.5%
US Market
1 Year Return
85.9%
DRNA
11.0%
US Biotechs
20.1%
US Market
Return vs Industry: DRNA exceeded the US Biotechs industry which returned 11% over the past year.
Return vs Market: DRNA exceeded the US Market which returned 20.1% over the past year.
Shareholder returns
| DRNA | Industry | Market | |
|---|---|---|---|
| 7 Day | -2.0% | -0.5% | 1.5% |
| 30 Day | -0.4% | 0.6% | 1.4% |
| 90 Day | -11.4% | 9.3% | 8.7% |
| 1 Year | 85.9%85.9% | 12.0%11.0% | 22.7%20.1% |
| 3 Year | 630.9%630.9% | 16.9%13.6% | 50.1%40.5% |
| 5 Year | -15.4%-15.4% | -1.5%-6.2% | 73.1%54.1% |
Price Volatility Vs. Market
How volatile is Dicerna Pharmaceuticals's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 weeks ago | Simply Wall St
Is Dicerna Pharmaceuticals, Inc.'s (NASDAQ:DRNA) CEO Being Overpaid?1 month ago | Simply Wall St
Co-Founder Douglas Fambrough Just Sold A Bunch Of Shares In Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA)4 months ago | Simply Wall St
Our Take On Dicerna Pharmaceuticals, Inc.'s (NASDAQ:DRNA) CEO SalaryValuation
Is Dicerna Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: DRNA ($21.27) is trading below our estimate of fair value ($72.33)
Significantly Below Fair Value: DRNA is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: DRNA is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: DRNA is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate DRNA's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: DRNA is overvalued based on its PB Ratio (10.8x) compared to the US Biotechs industry average (3.2x).
Next Steps
Future Growth
How is Dicerna Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?
-0.5%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: DRNA is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: DRNA is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: DRNA is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: DRNA's revenue (16.8% per year) is forecast to grow faster than the US market (7.6% per year).
High Growth Revenue: DRNA's revenue (16.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if DRNA's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has Dicerna Pharmaceuticals performed over the past 5 years?
-15.0%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: DRNA is currently unprofitable.
Growing Profit Margin: DRNA is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: DRNA is unprofitable, and losses have increased over the past 5 years at a rate of -15% per year.
Accelerating Growth: Unable to compare DRNA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: DRNA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (66.2%).
Return on Equity
High ROE: DRNA has a negative Return on Equity (-73.98%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Next Steps
Financial Health
How is Dicerna Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: DRNA's short term assets ($320.4M) exceed its short term liabilities ($119.4M).
Long Term Liabilities: DRNA's short term assets ($320.4M) exceed its long term liabilities ($82.5M).
Debt to Equity History and Analysis
Debt Level: DRNA is debt free.
Reducing Debt: DRNA had no debt 5 years ago.
Balance Sheet
Inventory Level: DRNA has a low level of unsold assets or inventory.
Debt Coverage by Assets: Insufficient data to determine if DRNA's debt is covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable DRNA has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: DRNA is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 22.8% per year.
Next Steps
Dividend
What is Dicerna Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate DRNA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate DRNA's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if DRNA's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if DRNA's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of DRNA's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
2.4yrs
Average management tenure
CEO
Douglas Fambrough (50yo)
9.8yrs
Tenure
US$2,497,561
Compensation
Dr. Douglas M. Fambrough, III, Ph.D., is a Co-Founder Dicerna Pharmaceuticals, Inc. and has been its Chief Executive Officer and President since May 2010. Dr. Fambrough served as a Venture Partner at Oxfor ...
CEO Compensation Analysis
Compensation vs Market: Douglas's total compensation ($USD2.50M) is below average for companies of similar size in the US market ($USD3.76M).
Compensation vs Earnings: Douglas's compensation has increased whilst the company is unprofitable.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 9.8yrs | US$2.50m | 0.018% $261.6k | |
| Chief Financial Officer | 3.8yrs | US$1.25m | 0.028% $413.1k | |
| Executive VP of Research & Development and Chief Scientific Officer | 8.1yrs | US$1.29m | 0.0073% $106.4k | |
| Co-Founder & Member of Scientific Advisory Board | 0yrs | no data | no data | |
| Co-Founder & Chairman of Scientific Advisory Board | 11.3yrs | no data | no data | |
| Executive VP & COO | 0.4yrs | US$1.36m | 0.032% $464.9k | |
| Senior Vice President of Human Resources | 1yrs | no data | no data | |
| Senior Vice President of Corporate Operations & Alliance Management | 0.4yrs | no data | no data | |
| Senior Vice President of Program Development | 2.1yrs | no data | no data | |
| Chief Medical Officer | 2.7yrs | US$953.29k | 0.0052% $75.8k |
2.4yrs
Average Tenure
61yo
Average Age
Experienced Management: DRNA's management team is considered experienced (2.4 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 9.8yrs | US$2.50m | 0.018% $261.6k | |
| Co-Founder & Member of Scientific Advisory Board | 0yrs | no data | no data | |
| Co-Founder & Chairman of Scientific Advisory Board | 11.3yrs | no data | no data | |
| Independent Chairman of the Board | 1.1yrs | US$272.82k | no data | |
| Independent Director | 12.3yrs | US$272.39k | no data | |
| Member of Scientific Advisory Board | 11.3yrs | no data | no data | |
| Independent Director | 2.8yrs | US$260.14k | no data | |
| Independent Director | 3.7yrs | US$265.63k | no data | |
| Independent Director | 1.5yrs | US$269.96k | no data | |
| Independent Director | 0.4yrs | no data | no data |
3.7yrs
Average Tenure
61yo
Average Age
Experienced Board: DRNA's board of directors are considered experienced (3.7 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: DRNA insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 45.5%.
Top Shareholders
Company Information
Dicerna Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Dicerna Pharmaceuticals, Inc.
- Ticker: DRNA
- Exchange: NasdaqGS
- Founded: 2006
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$1.456b
- Shares outstanding: 68.43m
- Website: https://www.dicerna.com
Number of Employees
Location
- Dicerna Pharmaceuticals, Inc.
- 87 Cambridgepark Drive
- Cambridge
- Massachusetts
- 2140
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| DRNA | NasdaqGS (Nasdaq Global Select) | Yes | Common Stock | US | USD | Jan 2014 |
| DPL | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Jan 2014 |
Biography
Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases, and cardiovascular diseases. Its principal development programs include DCR-PHXC for the treatment of primary hyperoxaluria; DCR-HBVS for the treatment of chronic hepatitis B virus infection; and a program for an undisclosed rare liver disease. The company’s development programs also comprise additional rare disease programs; a program for the treatment of hypercholesterolemia; and various programs in various therapeutic areas involving liver function. Dicerna Pharmaceuticals, Inc. has strategic collaborations with Eli Lilly and Company, Alexion Pharmaceuticals, Inc., and Boehringer Ingelheim International GmbH. The company was founded in 2006 and is headquartered in Cambridge, Massachusetts.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/02/17 01:09 |
| End of Day Share Price | 2020/02/14 00:00 |
| Earnings | 2019/09/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.